5,6,7,8-四氢吡啶并[3,4-D]嘧啶 | 781595-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 5,6,7,8-四氢吡啶并[3,4-D]嘧啶
• 中文别名: 5,6,7,8-四氢吡啶并[3,4-d]嘧啶
• 英文名称: mono5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine
• 英文别名: 5,6,7,8-tetrahydropyridino[3,4-d]pyrimidine；5,6,7,8-tetrahydro-1,3,7-triazanaphthalene；5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine；5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin；5,8-dihydro-6H-pyridino[3,4-d]pyrimidine；6,7-dihydro-5H-pyridino[3,4-d]pyrimidine；6,8-dihydro-5H-pyridino[3,4-d]pyrimidine；5,8-dihydro-6H-pyrido[3,4-d]pyrimidine；6,8-dihydro-5H-pyrido[3,4-d]pyrimidine；6,8-dihydro-5H-pyrido[3,4-d]pyrimidin；5H,6H,7H,8H-pyrido[3,4-d]pyrimidine；5H,6H,7H,8H-pyrido[3,4-d]pyrimidin
• CAS: 781595-43-5
• 化学式: C₇H₉N₃
• mdl: MFCD08703280
• 分子量: 135.169
• InChiKey: WGJUBVJZKNTGRC-UHFFFAOYSA-N

物化性质

• 沸点：
  277.1±30.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢吡啶并[3,4-D]嘧啶 、 (3'R,4S,6'R,7'S,8'E,11'S,12'R)-7-chloro-7'-methoxy-11',12'-dimethyl-13',13',15'-trioxospiro[2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-7'-carbaldehyde 在 N,N-二异丙基乙胺 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 58.17h， 生成 (1S,3’R,6’R,7’S,8’E,11’S,12’R)-6-chloro-7’-(5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-ylmethyl)-7’-methoxy-11’,12’-dimethyl-3,4-dihydro-2H,15’H-spiro[naphthalene-1,22’-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0~3,6~.0~19,24~]pentacosa[8,16,18,24]tetraen]-15’-one 13’,13’-dioxide
  参考文献：
  名称：

  [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  [FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1

  摘要：

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。

  公开号：

  WO2018183418A1

文献信息

• [EN] INDANE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES INDANE UTILISES COMME ANTAGONISTES DE CCR5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004055012A1

  公开（公告）日：2004-07-01

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及公式(I)的化合物，或其药用可接受的衍生物，用于治疗CCR5相关疾病和障碍，例如，用于抑制HIV复制，预防或治疗HIV感染，以及治疗由此导致的获得性免疫缺陷综合症（艾滋病）。
• ESTROGEN MODULATORS
  申请人：Bailey Simon

  公开号：US20070149564A1

  公开（公告）日：2007-06-28

  The present application is directed to a new class of isoxazoles and their use as estrogen modulators.

  本申请涉及一种新型异噁唑类化合物及其作为雌激素调节剂的用途。
• Inducible nitric oxide synthase dimerization inhibitors
  申请人：Gahman C. Timothy

  公开号：US20060116515A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR 4 , N, NR 4 , S, and O; U is selected from the group consisting of CR 10 and N; V is selected from the group consisting of CR 4 and N; W and W′ are independently selected from the group consisting of CH 2 , CR 7 R 8 , NR 9 , O, N(O), S(O) q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

  本发明涉及化合物和方法，用作一氧化氮合酶的抑制剂。本发明的某些化合物具有以下结构式： 其中T、X和Y分别选自CR 4 、N、NR 4 、S和O组成的群；U选自CR 10 和N组成的群；V选自CR 4 和N组成的群；W和W′分别选自CH 2 、CR 7 R 8 、NR 9 、O、N(O)、S(O) q 和C(O)组成的群；n、m和p分别是从0到5的整数；q为0、1或2；其他取代基如本文所定义。本发明的其他化合物具有如本文所定义的结构式。本文还公开了包含本发明化合物的药物组合物。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• [EN] 5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES<br/>[FR] COMPOSÉS DE 5,6,7,8-TÉTRAHYDROPYRIDO[3,4-D]PYRIMIDINE, LEUR UTILISATION COMME INHIBITEURS DE LA MTOR KINASE ET DE LA PI3 KINASE, ET LEURS SYNTHÈSES
  申请人：WYETH LLC

  公开号：WO2010120996A1

  公开（公告）日：2010-10-21

  A compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  公式I的化合物：或其药用可接受的盐，其中组成变量如本文所述，包含该化合物的组合物，以及制造和使用该化合物的方法。